No Data
No Data
Hubei Jumpcan Pharmaceutical (600566.SH): The repurchase period has expired and the company has repurchased 0.11% of its own shares.
On July 4th, Gelonhui reported that Hubei Jumpcan Pharmaceutical (600566.SH) completed the buyback through centralized bidding trading of the company's stock repurchase special securities account, accumulating 1,051,700 shares of the company's stock, accounting for 0.11% of the current total share capital of the company, at a maximum buyback price of 34.82 yuan per share, a minimum price of 27.19 yuan per share, and an average buyback price of 28.64 yuan per share, using a total amount of funds of 30,123,799.88 yuan (excluding transaction costs), as of July 3, 2024, when the buyback deadline expires.
Hubei Jumpcan Pharmaceutical Obtains Drug Registration for Antibiotic Injection; Shares Down 3%
Hubei Jumpcan Pharmaceutical (SHA:600566) received the drug registration certificate for its antibiotic drug, levofloxacin sodium chloride injection, from the State Drug Administration. The company sa
Hubei Jumpcan Pharmaceutical (600566.SH): Levofloxacin Sodium Chloride Injection Obtains Pharmaceutical Registration Certificate.
On June 26, Gelunhui reported that Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Jumpcan Pharmaceutical Group Co., Ltd. (referred to as 'Jumpcan Limited') received the Drug Registration Certificate for Levofloxacin Sodium Chloride Injection issued and approved by the National Medical Products Administration. Levofloxacin is the levorotatory form of ofloxacin, with its antibacterial activity about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase and inhibit bacterial DNA replication.
Hubei Jumpcan Pharmaceutical Gets Drug Registration Certificate for Allergy Drug; Shares Slide 3%
Hubei Jumpcan Pharmaceutical (SHA:600566) received the drug registration certificate for the fexofenadine hydrochloride dry suspension from the State Drug Administration, according to a Thursday filin
Jichuan Pharmaceutical (600566.SH): Fexofenadine hydrochloride dry suspension obtained drug registration certificate
On June 19th, Ge Long Hui reported that Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Hubei Jumpcan Pharmaceutical Group Co., Ltd (referred to as Jumpcan Limited), has received the Drug Registration Certificate for the Hydrochloride Fexofenadine Hydrochloride Dry Suspension, approved and issued by the National Medical Products Administration. Hydrochloride fexofenadine hydrochloride is a second-generation H1 receptor antagonist that can selectively block H1 receptors. It is the main active metabolite of terfenadine and has anti-histamine activity.
Is It Smart To Buy Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) Before It Goes Ex-Dividend?
Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) is about to trade ex-dividend in the next 3 days. The ex-dividend date is one business day before a company's record date, which is the date on wh
No Data